Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Emily W Hogeland, Tarah S Somers, Luke Yip, Suzanne Doyon, Carrie A Redlich, Andrea D Orsey, Craig B Woda, Suzannah T Swan, Henry M Feder
Two siblings aged 5 and 15 years from Connecticut were hospitalized with petechial rash, oral mucositis, and severe thrombocytopenia approximately 10 days after they played with a jar of elemental mercury they found in their home. Before the mercury exposure was disclosed, the siblings were treated with platelet transfusions, intravenous immune globulin (IVIG) for possible immune thrombocytopenic purpura, and antibiotics for possible infectious causes. When their conditions did not improve after 6 days, poison control facilitated further questioning about toxic exposures including mercury, testing for mercury, and chelation with dimercaptosuccinic acid...
September 22, 2023: MMWR. Morbidity and Mortality Weekly Report
#2
JOURNAL ARTICLE
Benjamin J Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Brian D Weiss, Michelle Choe, Jennifer H Foster, Navin Pinto, Daniel A Morgenstern, Margarida Simão Rafael, Keri A Streby, Rachel N Zeno, Rajen Mody, Sahr Yazdani, Ami V Desai, Margaret E Macy, Suzanne Shusterman, Sara M Federico, Rochelle Bagatell
PURPOSE: Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) therapy. PATIENTS AND METHODS: Patients eligible for this retrospective study were age < 30 years at diagnosis of HRNB and received ≥ 1 cycle of I/T/DIN/GM-CSF for relapsed or progressive disease...
January 20, 2023: Journal of Clinical Oncology
#3
JOURNAL ARTICLE
James R Wright, Suzanne Chan, Eric K Morgen, Raymond T A Maung, Marie-Anne Brundler, Dina El Demellawy, Robert B Fraser, Kyle C Kurek, Fergall Magee, Elizabeth Nizalik, Luc L Oligny, Gino R Somers, Camelia Stefanovici, Jefferson Terry
BACKGROUND: Workload measurement is important to help determine optimal staffing and workload distribution for pathology laboratories. The Level 4 Equivalent (L4E) System is the most widely used Anatomical Pathology (AP) workload measurement tool in Canada. However, it was initially not developed with subspecialties in mind. METHODS: In 2016, a Pan-Canadian Pediatric-Perinatal Pathology Workload Committee (PCPPPWC) was organized to adapt the L4E System to assess Pediatric-Perinatal Pathology workload...
September 8, 2022: Pediatric and Developmental Pathology
#4
JOURNAL ARTICLE
Jurjen J Luykx, Dore Loef, Bochao Lin, Linda van Diermen, Jasper O Nuninga, Eric van Exel, Mardien L Oudega, Didi Rhebergen, Sigfried N T M Schouws, Philip van Eijndhoven, Esmée Verwijk, Didier Schrijvers, Tom K Birkenhager, Karen M Ryan, Baer Arts, Suzanne C van Bronswijk, Gunter Kenis, Geert Schurgers, Bernhard T Baune, Martijn Arns, Edwin E van Dellen, Metten Somers, Iris E C Sommer, Marco P Boks, Sinan Gülöksüz, Declan M McLoughlin, Annemiek Dols, Bart P F Rutten
BACKGROUND: Electroconvulsive therapy (ECT) is the most effective treatment for severe major depressive episodes (MDEs). Nonetheless, firmly established associations between ECT outcomes and biological variables are currently lacking. Polygenic risk scores (PRSs) carry clinical potential, but associations with treatment response in psychiatry are seldom reported. Here, we examined whether PRSs for major depressive disorder, schizophrenia (SCZ), cross-disorder, and pharmacological antidepressant response are associated with ECT effectiveness...
October 24, 2021: Biological Psychiatry
#5
JOURNAL ARTICLE
Curt J Daniels, Saurabh Rajpal, Joel T Greenshields, Geoffrey L Rosenthal, Eugene H Chung, Michael Terrin, Jean Jeudy, Scott E Mattson, Ian H Law, James Borchers, Richard Kovacs, Jeffrey Kovan, Sami F Rifat, Jennifer Albrecht, Ana I Bento, Lonnie Albers, David Bernhardt, Carly Day, Suzanne Hecht, Andrew Hipskind, Jeffrey Mjaanes, David Olson, Yvette L Rooks, Emily C Somers, Matthew S Tong, Jeffrey Wisinski, Jason Womack, Carrie Esopenko, Christopher J Kratochvil, Lawrence D Rink
IMPORTANCE: Myocarditis is a leading cause of sudden death in competitive athletes. Myocardial inflammation is known to occur with SARS-CoV-2. Different screening approaches for detection of myocarditis have been reported. The Big Ten Conference requires comprehensive cardiac testing including cardiac magnetic resonance (CMR) imaging for all athletes with COVID-19, allowing comparison of screening approaches. OBJECTIVE: To determine the prevalence of myocarditis in athletes with COVID-19 and compare screening strategies for safe return to play...
September 1, 2021: JAMA Cardiology
#6
JOURNAL ARTICLE
Stuart D Faulkner, Suzanne Sayuri Ii, Chi Pakarinen, Fabian Somers, Maria Jose Vicente Edo, Lucia Prieto Remon, Ana Diaz Ponce, Dianne Gove, Elisa Ferrer, Begonya Nafria, Neil Bertelsen, Mathieu Boudes, Nicholas Brooke, Alexandra Moutet, Nick Fahy
BACKGROUND: The holistic evolution of patient engagement in medicines development requires a more detailed understanding of the needs of all involved stakeholders, and one that better accounts for the specific needs of some potentially vulnerable patient populations and key stages in medicines development. OBJECTIVE: The purpose of this convergent mixed-methods study was to better understand the needs of different stakeholders concerning patient engagement at three key stages in medicines development: research priority setting, clinical trial design and early dialogues with Health Technology Assessment bodies and regulators...
February 17, 2021: Health Expectations: An International Journal of Public Participation in Health Care and Health Policy
#7
JOURNAL ARTICLE
Rianne van Lieshout, Lidwine W Tick, Daphne de Laat, Stephanie Custers, Ingeborg M Dekker, Madieke D Douma, Doris Kalter, Suzanne Kranenburg, Debbie van der Lee, Patricia Rhoon-Bruijnzeel, Ien Schlösser, Maaike Somer, Claudia J van Tilborg, Willy K Visser, Harry C Schouten, Sandra Beijer
BACKGROUND & AIMS: The level of adherence to the updated guidelines of The European Societies for Clinical Nutrition and Metabolism (ESPEN) and for Blood and Marrow Transplantation (EBMT) on nutrition in intensively treated adult acute myeloid leukemia (AML) patients in clinical practice is unknown. The aim of this nationwide survey was to investigate ESPEN/EBMT nutritional guideline adherence during intensive AML treatment, variation in nutrition support practices among hospitals and whether these practices changed after guideline publication...
October 2020: Clinical Nutrition ESPEN
#8
JOURNAL ARTICLE
Loes Linsen, Kimberly Vanhees, Evi Vanoppen, Kim Ulenaers, Suzanne Driessens, Joris Penders, Veerle Somers, Piet Stinissen, Jean-Luc Rummens
Irreproducibility of research results is one of the major contributing factors to the failure of translating basic research results into tangible bedside progress. To address this, the University Biobank Limburg (UBiLim) was founded by a collaboration between Hasselt University, the Hospital East-Limburg, and the Jessa Hospital. This paper describes the evolution of this process and the barriers encountered on the way. UBiLim evolved from an archival collection over a single-site biobank into a federated structure, supporting translational research at the founding institutions...
2019: Frontiers in Medicine
#9
JOURNAL ARTICLE
Marjan Vanheusden, Bieke Broux, Suzanne P M Welten, Liesbet M Peeters, Eleni Panagioti, Bart Van Wijmeersch, Veerle Somers, Piet Stinissen, Ramon Arens, Niels Hellings
Cytomegalovirus (CMV) is a latent virus which causes chronic activation of the immune system. Here, we demonstrate that cytotoxic and pro-inflammatory CD4+ CD28null T cells are only present in CMV seropositive donors and that CMV-specific Immunoglobulin (Ig) G titers correlate with the percentage of these cells. In vitro stimulation of peripheral blood mononuclear cells with CMVpp65 peptide resulted in the expansion of pre-existing CD4+ CD28null T cells. In vivo, we observed de novo formation, as well as expansion of CD4+ CD28null T cells in two different chronic inflammation models, namely the murine CMV (MCMV) model and the experimental autoimmune encephalomyelitis (EAE) model for multiple sclerosis (MS)...
April 6, 2017: Scientific Reports
#10
JOURNAL ARTICLE
Nicole H T M Dukers-Muijrers, Carlijn Somers, Hanneke de Graaf, Suzanne Meijer, Christian J P A Hoebe
BACKGROUND: Non-volitional sex (NVS) in young people continues to be a major public health problem with long-term negative health outcomes. For the first time, the prevalence of different types of NVS and associated factors are compared between young people with same-sex sexual activities and those who have not. METHODS: We obtained data from 10,401 young women and men (aged 12 to 25 years) who participated in a population study on sexual health, the Netherlands...
2015: PloS One
#11
RANDOMIZED CONTROLLED TRIAL
Howard Trachtman, Suzanne Vento, Emily Herreshoff, Milena Radeva, Jennifer Gassman, Daniel T Stein, Virginia J Savin, Mukut Sharma, Jochen Reiser, Changli Wei, Michael Somers, Tarak Srivastava, Debbie S Gipson
BACKGROUND: Patients with resistant focal segmental glomerulosclerosis (FSGS) who are unresponsive to corticosteroids and other immunosuppressive agents are at very high risk of progression to end stage kidney disease. In the absence of curative treatment, current therapy centers on renoprotective interventions that reduce proteinuria and fibrosis. The FONT (Novel Therapies for Resistant FSGS) Phase II clinical trial (NCT00814255, Registration date December 22, 2008) was designed to assess the efficacy of adalimumab and galactose compared to standard medical therapy which was comprised of lisinopril, losartan, and atorvastatin...
July 22, 2015: BMC Nephrology
#12
JOURNAL ARTICLE
Allison Christian, Shawna V Hudson, Suzanne M Miller, Alicja Bator, Pamela A Ohman-Strickland, Robert A Somer, Jeanne Ferrante
BACKGROUND: Obese breast cancer survivors (BCSs) are impacted by diminished quality of life (QOL), multiple comorbid conditions, and poor disease outcomes. Despite national guidelines recommending a healthy weight to improve QOL and outcomes posttreatment, support and education are not routinely provided to BCSs in primary care. To fill this gap, we assessed perceptions of primary care received among BCSs by weight status. METHODS: Cross-sectional surveys were administered to early-stage BCSs (N = 188) from 2 New Jersey cancer centers between May 2012 and July 2013...
January 2015: Health Services Research and Managerial Epidemiology
#13
JOURNAL ARTICLE
Anthony J Bleyer, Stanislav Kmoch, Corinne Antignac, Vicki Robins, Kendrah Kidd, John R Kelsoe, Gerald Hladik, Philip Klemmer, Stephen J Knohl, Steven J Scheinman, Nam Vo, Ann Santi, Alese Harris, Omar Canaday, Nelson Weller, Peter J Hulick, Kristen Vogel, Frederick F Rahbari-Oskoui, Jennifer Tuazon, Constantinos Deltas, Douglas Somers, Andre Megarbane, Paul L Kimmel, C John Sperati, Avi Orr-Urtreger, Shay Ben-Shachar, David A Waugh, Stella McGinn, Anthony J Bleyer, Katerina Hodanová, Petr Vylet'al, Martina Živná, Thomas C Hart, P Suzanne Hart
BACKGROUND AND OBJECTIVES: The genetic cause of medullary cystic kidney disease type 1 was recently identified as a cytosine insertion in the variable number of tandem repeat region of MUC1 encoding mucoprotein-1 (MUC1), a protein that is present in skin, breast, and lung tissue, the gastrointestinal tract, and the distal tubules of the kidney. The purpose of this investigation was to analyze the clinical characteristics of families and individuals with this mutation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Families with autosomal dominant interstitial kidney disease were referred for genetic analysis over a 14-year period...
March 2014: Clinical Journal of the American Society of Nephrology: CJASN
#14
RANDOMIZED CONTROLLED TRIAL
Maaike G J Gademan, Henk J van Exel, Hedde van de Vooren, Joris C W Haest, Johannes van Pelt, Arnoud van der Laarse, Suzanne C Cannegieter, Carolien M H B Lucas, Soeresh Somer, Harriette F Verwey, Martin J Schalij, Ernst E van der Wall, Cees A Swenne
BACKGROUND: The mechanism of the beneficial effects of exercise training on autonomic derangement and neurohumoral activation in chronic heart failure (CHF) is largely unexplained. In our here-presented hypothesis-generating study we propose that part of these effects is mediated by the exercise-accompanying somatosensory nerve traffic. To demonstrate this, we compared the effects of periodic electrical somatosensory stimulation in patients with CHF with the effects of exercise training and with usual care...
October 9, 2013: International Journal of Cardiology
#15
RANDOMIZED CONTROLLED TRIAL
James P Stevenson, Corey J Langer, Robert A Somer, Tracey L Evans, Kumar Rajagopalan, Kimberly Krieger, Mona Jacobs-Small, Nikolas Dyanick, Barry Milcarek, Susan Coakley, Suzanne Walker, Beth Eaby-Sandy, Alexandre Hageboutros
BACKGROUND: The authors performed a phase 2 study of bevacizumab plus pemetrexed and carboplatin followed by maintenance bevacizumab in patients with advanced, nonsquamous nonsmall cell lung cancer. METHODS: Previously untreated patients with advanced, nonsquamous nonsmall cell lung cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1 received bevacizumab 15 mg/kg, pemetrexed 500 mg/m(2) and carboplatin at an area under the concentration-time curve of 6 intravenously on day 1 every 21 days...
November 15, 2012: Cancer
#16
RANDOMIZED CONTROLLED TRIAL
Howard Trachtman, Suzanne Vento, Debbie Gipson, Larysa Wickman, Jennifer Gassman, Melanie Joy, Virginia Savin, Michael Somers, Maury Pinsk, Tom Greene
BACKGROUND: The lack of adequate randomized clinical trials (RCT) has hindered identification of new therapies that are safe and effective for patients with primary focal segmental glomerulosclerosis (FSGS), especially in patients who fail to respond to corticosteroids and immunosuppressive therapies. Recent basic science advances have led to development of alternative treatments that specifically target aberrant pathways of fibrosis which are relevant to disease progression in FSGS. There is a need for a flexible Phase II study design which will test such novel antifibrotic strategies in order to identify agents suitable for phase III testing...
February 10, 2011: BMC Nephrology
#17
JOURNAL ARTICLE
Ludovic de Beaucoudrey, Arina Samarina, Jacinta Bustamante, Aurélie Cobat, Stéphanie Boisson-Dupuis, Jacqueline Feinberg, Saleh Al-Muhsen, Lucile Jannière, Yoann Rose, Maylis de Suremain, Xiao-Fei Kong, Orchidée Filipe-Santos, Ariane Chapgier, Capucine Picard, Alain Fischer, Figen Dogu, Aydan Ikinciogullari, Gonul Tanir, Sami Al-Hajjar, Suliman Al-Jumaah, Husn H Frayha, Zobaida AlSum, Sulaiman Al-Ajaji, Abdullah Alangari, Abdulaziz Al-Ghonaium, Parisa Adimi, Davood Mansouri, Imen Ben-Mustapha, Judith Yancoski, Ben-Zion Garty, Carlos Rodriguez-Gallego, Isabel Caragol, Necil Kutukculer, Dinakantha S Kumararatne, Smita Patel, Rainer Doffinger, Andrew Exley, Olle Jeppsson, Janine Reichenbach, David Nadal, Yaryna Boyko, Barbara Pietrucha, Suzanne Anderson, Michael Levin, Liliane Schandené, Kinda Schepers, André Efira, Françoise Mascart, Masao Matsuoka, Tatsunori Sakai, Claire-Anne Siegrist, Klara Frecerova, Renate Blüetters-Sawatzki, Jutta Bernhöft, Joachim Freihorst, Ulrich Baumann, Darko Richter, Filomeen Haerynck, Frans De Baets, Vas Novelli, David Lammas, Christiane Vermylen, David Tuerlinckx, Chris Nieuwhof, Malgorzata Pac, Walther H Haas, Ingrid Müller-Fleckenstein, Bernhard Fleckenstein, Jacob Levy, Revathi Raj, Aileen Cleary Cohen, David B Lewis, Steven M Holland, Kuender D Yang, Xiaochuan Wang, Xiaohong Wang, Liping Jiang, Xiqiang Yang, Chaomin Zhu, Yuanyuan Xie, Pamela Pui Wah Lee, Koon Wing Chan, Tong-Xin Chen, Gabriela Castro, Ivelisse Natera, Ana Codoceo, Alejandra King, Liliana Bezrodnik, Daniela Di Giovani, Maria Isabel Gaillard, Dewton de Moraes-Vasconcelos, Anete Sevciovic Grumach, Alberto Jose da Silva Duarte, Ruth Aldana, Francisco Javier Espinosa-Rosales, Mohammed Bejaoui, Ahmed Aziz Bousfiha, Jamila El Baghdadi, Namik Ozbek, Guzide Aksu, Melike Keser, Ayper Somer, Nevin Hatipoglu, Cigdem Aydogmus, Suna Asilsoy, Yildiz Camcioglu, Saniye Gülle, Tuba T Ozgur, Meteran Ozen, Matias Oleastro, Andrea Bernasconi, Setareh Mamishi, Nima Parvaneh, Sergio Rosenzweig, Ridha Barbouche, Sigifredo Pedraza, Yu Lung Lau, Mohammad S Ehlayel, Claire Fieschi, Laurent Abel, Ozden Sanal, Jean-Laurent Casanova
Interleukin-12 receptor β1 (IL-12Rβ1) deficiency is the most common form of Mendelian susceptibility to mycobacterial disease (MSMD). We undertook an international survey of 141 patients from 102 kindreds in 30 countries. Among 102 probands, the first infection occurred at a mean age of 2.4 years. In 78 patients, this infection was caused by Bacille Calmette-Guérin (BCG; n = 65), environmental mycobacteria (EM; also known as atypical or nontuberculous mycobacteria) (n = 9) or Mycobacterium tuberculosis (n = 4)...
November 2010: Medicine (Baltimore)
#18
JOURNAL ARTICLE
Richard Angell, Nicola M Aston, Paul Bamborough, Jacky B Buckton, Stuart Cockerill, Suzanne J deBoeck, Chris D Edwards, Duncan S Holmes, Katherine L Jones, Dramane I Laine, Shila Patel, Penny A Smee, Kathryn J Smith, Don O Somers, Ann L Walker
The biphenyl amides (BPAs) are a novel series of p38alpha MAP kinase inhibitor. The optimisation of the series to give compounds that are potent in an in vivo disease model is discussed. SAR is presented and rationalised with reference to the crystallographic binding mode.
August 1, 2008: Bioorganic & Medicinal Chemistry Letters
#19
JOURNAL ARTICLE
Gino R Somers, Maria Zielenska, Shaker Abdullah, Christopher Sherman, Suzanne Chan, Paul S Thorner
Synovial sarcoma accounts for between 6 and 10% of childhood sarcomas and histological diagnosis can be challenging, even for experienced pathologists. Several other tumors enter the differential diagnosis, including malignant peripheral nerve sheath tumor, Ewing sarcoma/primitive neuroectodermal tumor and undifferentiated sarcoma. Several recent reports utilizing expression array techniques have documented expression of the MYCN oncogene in synovial sarcoma. In order to more fully investigate this finding, a series of 12 synovial sarcomas and 29 other sarcomas (four malignant peripheral nerve sheath tumors, 15 Ewing sarcoma/primitive neuroectodermal tumors, 10 undifferentiated sarcomas) were examined for MYCN expression and gene amplification...
July 2007: Modern Pathology
#20
COMPARATIVE STUDY
Charles Kunsch, Jayraz Luchoomun, Xi-Lin Chen, Geraldine L Dodd, Kanika S Karu, Charles Q Meng, Elaine M Marino, Lyn K Olliff, J Daniel Piper, Fei-Hua Qiu, James A Sikorski, Patricia K Somers, Ki-Ling Suen, Suzanne Thomas, Anne M Whalen, Martin A Wasserman, Cynthia L Sundell
The pathogenesis of chronic inflammatory diseases, including rheumatoid arthritis, is regulated, at least in part, by modulation of oxidation-reduction (redox) homeostasis and the expression of redox-sensitive inflammatory genes including adhesion molecules, chemokines, and cytokines. AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid] is a novel, orally active, phenolic antioxidant and anti-inflammatory compound with antirheumatic properties...
May 2005: Journal of Pharmacology and Experimental Therapeutics
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
